Vaccination boosts naturally enhanced neutralizing breadth to SARS-CoV-2 one year after infection

Zijun Wang1,*, Frauke Muecksch2,*, Dennis Schaefer-Babajew1,*, Shlomo Finkin1,*, Charlotte Viant1,*, Christian Gaebler1,*, Christopher Barnes3, Melissa Cipolla1, Victor Ramos1, Thiago Y. Oliveira1, Alice Cho1, Fabian Schmidt2, Justin da Silva2, Eva Bednarski2, Mridushi Daga1, Martina Turroja1, Katrina G. Millard1, Mila Jankovic1, Anna Gazumyan1,4, Paul D. Bieniasz2,4, Marina Caskey1, Theodora Hatzioioannou2 and Michel C. Nussenzweig1,4

1Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
2Laboratory of Retrovirology, The Rockefeller University, New York, NY 10065, USA
3Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
4Howard Hughes Medical Institute

*equal contribution

Address correspondence to: Paul D. Bieniasz pbieniasz@rockefeller.edu; Marina Caskey mcaskey@rockefeller.edu; Theodora Hatzioioannou thatziio@rockefeller.edu; or Michel C. Nussenzweig nussen@rockefeller.edu
Over one year after its inception, the coronavirus disease-2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) remains difficult to control despite the availability of several excellent vaccines. Progress in controlling the pandemic is slowed by the emergence of variants that appear to be more transmissible and more resistant to antibodies\(^1,2\). Here we report on a cohort of 63 COVID-19-convalescent individuals assessed at 1.3, 6.2 and 12 months after infection, 41% of whom also received mRNA vaccines\(^3,4\). In the absence of vaccination antibody reactivity to the receptor binding domain (RBD) of SARS-CoV-2, neutralizing activity and the number of RBD-specific memory B cells remain relatively stable from 6 to 12 months. Vaccination increases all components of the humoral response, and as expected, results in serum neutralizing activities against variants of concern that are comparable to or greater than neutralizing activity against the original Wuhan Hu-1 achieved by vaccination of naïve individuals\(^2,5-8\). The mechanism underlying these broad-based responses involves ongoing antibody somatic mutation, memory B cell clonal turnover, and development of monoclonal antibodies that are exceptionally resistant to SARS-CoV-2 RBD mutations, including those found in variants of concern\(^4,9\). In addition, B cell clones expressing broad and potent antibodies are selectively retained in the repertoire over time and expand dramatically after vaccination. The data suggest that immunity in convalescent individuals will be very long lasting and that convalescent individuals who receive available mRNA vaccines will produce antibodies and memory B cells that should be protective against circulating SARS-CoV-2 variants. Should memory responses evolve in a similar manner in
vaccinated individuals, additional appropriately timed boosting with available vaccines could cover most circulating variants of concern.

We initially characterized immune responses to SARS-CoV-2 in a cohort of convalescent individuals 1.3 and 6.2 months after infection\(^3\). Between February 8 and March 26, 2021, 63 participants returned for a 12-month follow-up visit among whom 26 (41\%) had received at least one dose of either the Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines, on average 40 days before their study visit (Supplementary Table 1). Of the individuals that returned for a 12-month follow-up, 10\% had been hospitalized and the remainder had experienced relatively mild initial infections. Only 14\% of the individuals reported persistent long-term symptoms after 12 months, reduced from 44\% at the 6-month time point\(^4\). Symptom persistence was not associated with the duration and severity of acute disease or with vaccination status (Extended Data Fig. 1 a-c). All participants tested negative for active infection at the 12-month time point as measured by a saliva-based PCR assay \(^4\). The demographics and clinical characteristics of the participants are shown in Supplementary Tables 1 and 2.

**Plasma SARS-CoV-2 Antibody Reactivity**

Antibody reactivity in plasma to the RBD and nucleoprotein (N) were measured by enzyme-linked immunosorbent assay (ELISA)\(^3\). Convalescent participants who had not been vaccinated maintained most of their anti-RBD IgM (103\%), IgG (88\%), and IgA (72\%) titers between 6 and 12 months (Fig. 1a and Extended Data Fig. 2a-h). Consistent with previous reports\(^5\)-\(^8\), vaccination increased the anti-RBD plasma antibody levels, with IgG titers increasing by nearly 5-fold compared to unvaccinated individuals (Fig. 1a right). The 2 individuals who did not show
an increase had been vaccinated only 2 days before sample collection. In contrast to anti-RBD antibody titers that were relatively stable, anti-N antibody titers decreased significantly between 6 and 12 months irrespective of vaccination (Fig. 1b). Thus, persistence of humoral immunity to individual SARS-CoV-2 viral antigens differs, favoring longevity of anti-RBD over anti-N responses.

Plasma neutralizing activity in 63 participants was measured using an HIV-1 pseudotyped with the SARS-CoV-2 spike protein \(^3,4,10\) (Fig. 1c-e). Twelve-months after infection, the geometric mean half-maximal neutralizing titer (NT\(_{50}\)) for the 37 individuals that had not been vaccinated was 75, which was not significantly different from the same individuals at 6.2 months (Fig. 1d).

In contrast, the vaccinated individuals showed a geometric mean NT\(_{50}\) of 3,684, which was nearly 50-fold greater than unvaccinated individuals and disproportionately increased compared to anti-RBD IgG antibodies (Fig. 1a, d, and e). Neutralizing activity was directly correlated with IgG anti-RBD (Extended Data Fig.2i) but not with anti-N titers (Extended Data Fig.2k). We conclude that neutralizing titers remain relatively unchanged between 6 to 12 months after SARS-CoV-2 infection, and that vaccination further boosts this activity by nearly 50-fold.

To determine the neutralizing activity against circulating variants of concern/interest, we performed neutralization assays on HIV-1 virus pseudotyped with the S protein of the following SARS-CoV-2 variants of concern/interest: B.1.1.7, B.1.351, B.1.526 \(^1,11,12\). Twelve-months after infection neutralizing activity against the variants was generally lower than against wild-type SARS-CoV-2 virus in the same assay with the greatest loss of activity against B.1.351 (Fig. 1f). After vaccination the geometric mean NT\(_{50}\) rose to 11,493, 48,341 and 22,109 against B.1.351,
B.1.1.7 and B.1.526, respectively. These titers are an order of magnitude higher than the neutralizing titers achieved against the wild-type SARS-CoV-2 at the peak of the initial response in infected individuals and in naïve individuals receiving both doses of mRNA vaccines (Fig. 1d and 2,5-8).

Memory B cells

The memory B cell compartment serves as an immune reservoir that contains a diverse collection of antibodies13,14. To enumerate RBD-specific memory B cells, we performed flow cytometry using a biotin-labeled RBD3 (Fig. 2a upper panel, Extended Data Fig. 3a and b). In the absence of vaccination, the number of RBD specific memory B cells present at 12 months was only 1.35-fold lower than the earlier timepoint (p= 0.027, Fig. 2b). In contrast and consistent with previous reports5,8,15, convalescent individuals that received mRNA vaccines showed an average 8.6-fold increase in the number of circulating RBD specific memory B cells (Fig. 2b). B cells expressing antibodies that bound to both wild-type and K417N/E484K/N501Y mutant RBDs were also enumerated by flow cytometry (Fig. 2a lower panel, Extended Data Fig 3c). The number of variant RBD cross-reactive B cells was directly proportional to but 1.6 to 3.2-fold lower than wild-type RBD binding B cells (Fig. 2b).

The memory B cell compartment accumulates mutations and undergoes clonal evolution over the initial 6 months after infection4,9,16,17. To determine whether the memory compartment continues to evolve between 6 and 12 months, we obtained 1105 paired antibody heavy and light chain sequences from 10 individuals that were also assayed at the earlier time points, 6 of which were vaccinated (Fig. 2c, Extended Data Fig 3d, Supplementary Table 3). There were few significant
differences among the expressed IGHV and IGLV genes between vaccinated and un-vaccinated groups, or between the 1.3-, 6-month and 1 year time points (Extended Data Fig 4a-c)\(^{3,4}\). IGHV3-30 and IGHV3-53 remained over-represented irrespective of vaccination\(^{18,19}\) (Extended Data Fig 4a).

All individuals assayed at 12 months showed expanded clones of RBD-binding memory cells that expressed closely related IGHV and IGLV genes (Fig. 2c and d, Extended Data Fig 3d). The relative fraction of cells belonging to these clones varied from 7-54% of the repertoire with no significant difference between vaccinated and non-vaccinated groups. The overall clonal composition differed between 6 and 12 months in all individuals suggesting ongoing clonal evolution (Fig. 2c, Extended Data Fig 3d). Among the 89 clones found after 12 months, 61% were not previously detected and 39% were present at one of the earlier time points (Fig. 2c, Extended Data Fig 3d). In vaccinated individuals the increase in size of the memory compartment was paralleled by an increase in the absolute number of B cells representing all persistent clones (Fig. 2b and e, Extended Data Fig 5a). Thus, RBD specific memory B cell clones were re-expanded upon vaccination in all 6 convalescent individuals examined (Fig. 2c and e, Extended Data Fig 3d and Extended Data Fig 5a).

Somatic hypermutation of antibody genes continued between 6 and 12 months after infection (Fig. 2f). Slightly higher levels of mutation were found in individuals who had not been vaccinated compared to vaccinated individuals possibly due to recruitment of newly-formed memory cells into the expanded memory compartment of the vaccinated individuals (Fig. 2c-e, Extended Data Fig 5b). There was no significant difference in mutation between conserved and
newly arising clones at the 12-month time point in vaccinated individuals (Extended Data Fig 5c). Moreover, phylogenetic analysis revealed that sequences found at 6 and 12 months were intermingled and similarly distant from their unmutated common ancestors (Extended Data Fig 6). We conclude that clonal re-expansion of memory cells in response to vaccination is not associated with additional accumulation of large numbers of somatic mutations as might be expected if the clones were re-entering and proliferating in germinal centers.

Neutralizing Activity of Monoclonal Antibodies

To determine whether the antibodies obtained from memory B cells 12 months after infection bind to RBD we performed ELISAs (Fig.3a). 174 antibodies were tested by ELISA including: 1. 53 that were randomly selected from those that appeared only once and only after 1 year; 2. 91 that appeared as expanded clones or singlets at more than one time point; 3. 30 representatives of newly arising expanded clones (Supplementary Tables 4 and 5). Among the 174 antibodies tested, 173 bound to RBD indicating that the flow cytometry method used to identify B cells expressing anti-RBD antibodies was efficient (Supplementary Tables 4 and 5). The geometric mean ELISA half-maximal concentration (EC_{50}) of the antibodies obtained after 12 months was 2.6 ng/ml, which was significantly lower than at 6 months irrespective of vaccination and suggestive of an increase in affinity (Fig. 3a, Extended data Fig. 7 a and b and Supplementary Tables 4 and 5).

All 174 RBD binding antibodies obtained from the 12-month time point were tested for neutralizing activity in a SARS-CoV-2 pseudotype neutralization assay. When compared to the earlier time points from the same individuals, the geometric mean half maximal inhibitory
concentration (IC$_{50}$) improved from 171 ng/mL (1.3 months) to 116 ng/mL (6 months) to 79 ng/mL (12 months), with no significant difference between vaccinated and non-vaccinated individuals (Fig. 3b and Extended data Fig. 7c, Supplementary Table 4). The increased potency was especially evident in the antibodies expressed by expanded clones of B cells that were conserved for the entire observation period irrespective of vaccination (p=0.014, Fig. 3b right and c, Extended Data Fig 7e and Supplementary Table 5). The overall increase in neutralizing activity among conserved clones was due to accumulation of clones expressing antibodies with potent neutralizing activity and simultaneous loss of clones expressing antibodies with no measurable activity (p= 0.028, Fig 3b right pie charts). Consistent with this observation, antibodies obtained from clonally expanded B cells after 12 months were more potent than antibodies obtained from unique B cells at the same time point (p= 0.029, Fig 3b).

**Epitopes and Breadth of Neutralization**

To determine whether the loss of non-neutralizing antibodies over time was due to preferential loss of antibodies targeting specific epitopes, we performed BLI experiments in which a preformed antibody-RBD complex was exposed to a second monoclonal targeting one of 3 classes of structurally defined epitopes$^{3,20}$ (see schematic in Fig. 4a). We assayed 60 randomly selected antibodies with comparable neutralizing activity from the 1.3- and 12-month time points. The 60 antibodies were evenly distributed between the 2 time points and between neutralizers and non-neutralizers (Fig. 4). Antibody affinities for RBD were similar among neutralizers and non-neutralizers obtained at the same time point (Fig. 4b, Extended Data Figure 8). Although the differences were small, both neutralizers and non-neutralizers showed increased affinity over time (Fig. 4b, Extended Data Fig. 8). In competition experiments, all but 2 of the
30 non-neutralizing antibodies failed to inhibit binding of the class 1 (C105), 2 (C121 and C144) or 3 (C135) antibodies tested and therefore must bind to epitopes that do not overlap with the epitopes of these classes of antibodies (Fig. 4c, and Extended Data Fig. 9). In contrast, all but 2 of the 30 neutralizers blocked class 1, or 2 antibodies whose target epitopes are structural components of the RBD that interact with its cellular receptor, the angiotensin-converting enzyme 2\textsuperscript{20,21} (ACE2) (Fig. 4c and Extended Data Fig. 9). In addition, whereas 9 of the 15 neutralizing antibodies obtained after 1.3 months blocked both class 1 and 2 antibodies, only 1 of the 15 obtained after 12 months did so. In contrast to the earlier time point, 13 of 15 neutralizing antibodies obtained after 12 months only interfered with C121, a class 2 antibody\textsuperscript{3,20} (Fig. 4c and Extended Data Fig. 9). We conclude that neutralizing antibodies are retained and non-neutralizing antibodies targeting RBD surfaces that do not interact with ACE2 are removed from the repertoire over time.

To determine whether there was an increase in neutralization breadth over time, the neutralizing activity of the 60 antibodies was assayed against a panel of RBD mutants covering residues associated with circulating variants of concern: R346S, K417N, N440K, A475V, E484K and N501Y (Fig. 4d and Supplementary Table 6). Increased activity was evident against K417N, N440K, A475V, E484K and N501Y (Fig. 4d and Supplementary Table 6). We conclude that evolution of the antibody repertoire results in acquisition of neutralization breadth over time.

The increase in breadth and overall potency of memory B cell antibodies could be due to shifts in the repertoire, clonal evolution, or both. To determine whether changes in specific clones are associated with increases in affinity and breadth, we measured the relative affinity and
neutralizing breadth of pairs of antibodies expressed by expanded clones of B cells that were maintained in the repertoire over the entire observation period\textsuperscript{3,4}. SARS-CoV-2 neutralizing activity was not significantly correlated with affinity at either time point considered independently (Fig. 5a). However, there was a significant increase in overall affinity over time including in the 4 pairs of antibodies with no measurable neutralizing activity (Fig 5b and Supplementary Table 7). Neutralizing breadth was assayed for 15 randomly selected pairs of antibodies targeting epitopes assigned to the 3 dominant classes of neutralizing antibodies\textsuperscript{3,20,22,23}. Seven of the selected antibodies showed equivalent or decreased activity against wild-type SARS-CoV-2 after 12 months (Fig. 5c and Supplementary Table 8). However, neutralizing breadth increased between 1.3 and 12-months for all 15 pairs, even when neutralizing activity against the wild-type was unchanged or decreased (Fig. 5c and Supplementary Table 8). Only 1 of the 15 antibodies obtained after 1.3 months neutralized all the mutants tested (Fig. 5c). In contrast, 10 of the 15 antibodies obtained from the same clones after 12 months neutralized all variants tested with IC\textsubscript{50}s as low as 1 ng/ml against the triple mutant K417N/E484K/N501Y found in B.1.351 (Fig. 5c and Supplementary Table 8). In conclusion, continued clonal evolution of anti-SARS-CoV-2 antibodies over 12 months favors increasing potency and breadth resulting in monoclonal antibodies with exceptional activity against a broad group of variants.

Discussion

During immune responses activated B cells interact with cognate T cells and begin dividing before selection into the plasma cell, memory or germinal center B cell compartments based in part on their affinity for antigen\textsuperscript{14,24-28}. Whereas B cells expressing high affinity antibodies are
favored to enter the long-lived plasma cell compartment, the memory compartment is more

diverse and can develop directly from activated B cells or from a germinal center. Memory cells emanating from a germinal center carry more mutations than those that develop
directly from activated B cells because they undergo additional cycles of division.

Consistent with the longevity of bone marrow plasma cells, infection with SARS-CoV-2 leads to
persistent serum anti-RBD antibodies, and corresponding neutralizing responses. Nearly 93% of
the plasma neutralizing activity is retained between 6- and 12-months. Vaccination boosts the
neutralizing response by 1.5 orders of magnitude by inducing additional plasma cell
differentiation from the memory B cell compartment. Recruitment of evolved memory B cells
producing antibodies with broad and potent neutralizing activity into the plasma cell
compartment is likely to account for the exceptional serologic activity of vaccinated
convalescents against variants of concern.

Less is known about selection and maintenance of the memory B cell compartment. SARS-CoV-2 infection produces a memory compartment that continues to evolve over 12 months after
infection with accumulation of somatic mutations, emergence of new clones, and increasing
affinity all of which is consistent with long-term persistence of germinal centers. The increase in
activity against SARS-CoV-2 mutants parallels the increase in affinity and is consistent with the
finding that increasing the apparent affinity of anti-SARS-2 antibodies by dimerization or by
creating bi-specific antibodies also increases resistance to RBD mutations.
Continued antibody evolution in germinal centers requires antigen which can be retained in these structures over long periods of time\textsuperscript{26}. In addition, SARS-CoV-2 protein and nucleic acid has been reported in the gut for at least 2 months after infection\textsuperscript{4}. Irrespective of the source of antigen, antibody evolution favors epitopes overlapping with the ACE2 binding site on the RBD, possibly because these are epitopes that are preferentially exposed on trimeric spike protein or virus particles.

Vaccination after SARS-CoV-2 infection increases the number of RBD binding memory cells by over an order of magnitude by recruiting new B cell clones into memory and expanding persistent clones. The persistent clones expand without accumulating large numbers of additional mutations indicating that clonal expansion of human memory B cells does not require re-entry into germinal centers and occurs through the activated B cell compartment\textsuperscript{14,24-28}.

The remarkable evolution of breadth after infection and the robust enhancement of serologic responses and B cell memory achieved with mRNA vaccination suggests that convalescent individuals who are vaccinated should enjoy high levels of protection against emerging variants without a need to modify existing vaccines. If memory responses evolve in a similar manner in naive individuals that receive vaccines, additional appropriately timed boosting with available vaccines should lead to protective immunity against circulating variants.
Fig. 1: Plasma ELISAs and neutralizing activity. a-b, Plasma IgG antibody binding to SARS-CoV-2 RBD (a) and N protein (b), and plasma neutralizing activity (c–e) 12 months after infection.
(N=63). a and b, ELISA curves from non-vaccinated (black lines) individuals, as well as individuals who received one or two doses of a COVID-19 mRNA vaccine (blue lines), respectively (left panels). Area under the curve (AUC) over time in non-vaccinated and vaccinated individuals, as indicated (middle panels). Two individuals who received their first dose of vaccine 24-48 hours before sample collection are depicted in purple. Lines connect longitudinal samples. Numbers in red indicate geometric mean AUC at the indicated timepoint. Right most panel shows combined values as a dot plot for all individuals. c, ranked average NT50 at 1.3 months (light grey) and 6.2 months (dark grey), as well as at 12 months for non-vaccinated (orange) individuals, and individuals who received one or two doses (blue circles) of a COVID-19 mRNA vaccine, respectively. Two individuals who received their first dose of vaccine 24-48 hours before sample collection are depicted in purple. d, e, NT50 over time in non-vaccinated (d) and vaccinated individuals (e). Lines connect longitudinal samples from the same individual. Two individuals who received their first dose of vaccine 24-48 hours before sample collection are depicted in purple. Red numbers indicate the geometric mean NT50 at the indicated timepoint. Statistical significance in a, b, d and e was determined using Friedman Multiple Comparisons test. f, Plasma neutralizing activity against SARS-CoV-2 variants of concern. All experiments were performed at least in duplicate.
Fig. 2: Anti-SARS-CoV-2 RBD B cell memory. a, Representative flow cytometry plots showing dual AlexaFluor-647-RBD WT, or AlexaFluor-647-K417N/E484K/N501Y mutant and PE-RBD-binding B cells for 6 individuals. Vaccine recipients are indicated in red. Gating strategy is found in Extended Data Fig. 3a. Percentage of antigen-specific B cells is indicated. b. As in a, graph summarizes number of antigen binding memory B cells per 2 million B cells (Extended data Fig 5b and c) obtained at 1.3, 6.2 and 12 months from 40 randomly selected individuals (vaccinees n=20, and non-vaccinees, n=20). Each dot is one individual. Red horizontal bars indicate geometric mean values. Statistical significance was determined using two-tailed Mann–Whitney U-tests. c, Pie charts show the distribution of antibody sequences from 6 individuals after 1.3 or 6.2 (upper panel) or 12 months (lower panel). The number in the inner circle indicates the number of sequences analyzed for the individual denoted above the circle. Pie slice size is proportional to the number of clonally related sequences. The black outline indicates the frequency of clonally expanded sequences detected in each participant. Colored slices indicate persisting clones (same IGV and IGJ genes, with highly similar CDR3s) found at both timepoints in the same participant. Grey slices indicate clones unique to the timepoint. White indicates sequences isolated once, and white slices indicate singlets found at both timepoints. d, Circos plot depicts the relationship between antibodies that share V and J gene segment sequences at both IGH and IGL. Purple, green, and grey lines connect related clones, clones and singles, and singles to each other, respectively. e, Number of clonally expanded B cells (per 10 million B cells) at indicated time points in 6 individuals. Colors indicate shared clones appearing at different time points. Statistical significance was determined using Wilcoxon matched-pairs signed rank test. Vaccinees are marked in red. f, Number of somatic nucleotide mutations in the IGVH and IGVL in antibodies (also Supplementary table 3) obtained after 1.3 or 6.2 or 12 months from 10 donors (vaccinees,
n=6, non-vaccinees, n=4). Red horizontal bars indicate mean values. Statistical significance was
determined using two-tailed Mann–Whitney U-tests.
Fig. 3: Anti-SARS-CoV-2 RBD monoclonal antibodies. **a**, Graph shows the ELISA binding EC\textsubscript{50} (Y axis) for SARS-CoV-2 RBD by antibodies isolated at 1.3\textsuperscript{3} 6.2\textsuperscript{4} and 12 months after infection. Statistical significance was determined using the Kruskal-Wallis test. **b-c**, Graphs show anti-SARS-CoV-2 neutralizing activity of monoclonal antibodies measured by a SARS-CoV-2 pseudovirus neutralization assay\textsuperscript{3,10}. Half-maximal inhibitory concentration (IC\textsubscript{50}) values for antibodies isolated at 1.3\textsuperscript{3} 6.2\textsuperscript{4} and 12 months after infection. **b**, Wild-type SARS-CoV-2 (Wuhan-Hu-1 strain\textsuperscript{18}) neutralization by monoclonal antibodies. Each dot represents one antibody. Pie charts illustrate the fraction of non-neutralizing (IC\textsubscript{50} > 1000 ng/ml) antibodies (grey slices), inner circle shows number of antibodies tested. Horizontal bars and red numbers indicate geometric mean values. Statistical significance was determined through the Kruskal Wallis test with subsequent Dunn’s multiple comparisons. **c**, Heat map shows the neutralizing activity of clonally related antibodies against wt-SARS-CoV-2 over time. White tiles indicate no clonal relative at the respective time point. Clones are ranked from left to right by the potency of the 12-month progeny.
antibodies which are denoted below the tiles. For b and c, antibodies with IC$_{50}$ values above 1000 ng/ml were plotted at 1000 ng/ml. The average of two independent experiments is shown.
Fig. 4: Epitope targeting of anti-SARS-CoV-2 RBD antibodies. a, Schematic representation of the BLI experiment (left) and IC$_{50}$ values for randomly selected neutralizing (middle) and non-neutralizing (right) antibodies isolated at 1.3- and 12-months post-infection. Red horizontal bars indicate geometric mean values. Statistical significance was determined using Mann-Whitney test.

b, K$_D$ values of the neutralizing (green) and non-neutralizing (red) antibodies isolated at 1.3 and 12 months after infection. Red horizontal bars indicate geometric mean values. Statistical significance was determined using Kruskal Wallis test with subsequent Dunn’s multiple comparisons. BLI traces can be found in Extended data Fig. 8.

c, Biolayer interferometry results was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.
presented as a heat-map of relative inhibition of Ab2 binding to the preformed Ab1-RBD complexes (grey=no binding, orange=intermediate binding, red=high binding). Values are normalized through the subtraction of the autologous antibody control. BLI traces can be found in Extended Data Fig 9. d, Neutralization of the indicated mutants for antibodies shown in panel a-c. Pie charts illustrate the fraction of antibodies that are poorly/non-neutralizing (IC$_{50}$ 100-1000 ng/ml, red), intermediate neutralizing (IC$_{50}$ 10-100 ng/ml, pink) and potently neutralizing (IC$_{50}$ 0-10 ng/ml, white) for each mutant. Number in inner circle shows number of antibodies tested.
**Fig. 5:** Clonal evolution of anti-SARS-CoV-2 RBD antibodies. 

**a,** Graphs show affinities (Y axis) plotted against neutralization activity (X axis) for clonal antibody pairs isolated 1.3 (top) and 12 months (bottom) after infection. 

**b,** BLI affinity measurements for same paired 1.3- and 12-month antibodies as in **a.**

**c,** IC₅₀ values for 15 neutralizing antibody pairs against indicated mutant SARS-CoV-2 pseudoviruses. Antibodies are divided into groups i-iii, based on neutralizing activity: (i) potent clonal pairs that do not improve over time, (ii) clonal pairs that show increased activity over time, and (iii) clonal pairs showing decreased neutralization activity after 12 months. Antibody class assignment based on initial (1.3m) sensitivity to mutation is indicated on the right. Red stars indicate antibodies that neutralize all RBD mutants tested. Color gradient indicates IC₅₀ values ranging from 0 (white) to 1000 ng/ml (red).
Methods

Study participants.

Previously enrolled study participants were asked to return for a 12-month follow-up visit at the Rockefeller University Hospital in New York from February 8 to March 26, 2021. Eligible participants were adults with a history of participation in both prior study visits of our longitudinal cohort study of COVID-19 recovered individuals. All participants had a confirmed history of SARS-CoV-2 infection, either diagnosed during the acute infection by RT-PCR or retrospectively confirmed by seroconversion. Exclusion criteria included presence of symptoms suggestive of active SARS-CoV-2 infection. Most study participants were residents of the Greater New York City tri-state region and were asked to return approximately 12 months after the time of onset of COVID-19 symptoms. Participants presented to the Rockefeller University Hospital for blood sample collection and were asked about potential symptom persistence since their 6.2-month study visit, laboratory-confirmed episodes of reinfection with SARS-CoV-2, and whether they had received any COVID-19 related treatment or SARS-CoV-2 vaccination in the interim. Detailed characteristics of the symptomology and severity of the acute infection, symptom kinetics, and the immediate convalescent phase (7 weeks post-symptom onset until 6.2-month visit) have been reported previously. Participants that presented with persistent symptoms attributable to COVID-19 were identified on the basis of chronic shortness of breath or fatigue, deficit in athletic ability and/or three or more additional long-term symptoms such as persistent unexplained fevers, chest pain, new-onset cardiac sequelae, arthralgias, impairment of concentration/mental acuity, impairment of sense of smell/taste, neuropathy or cutaneous findings as previously described. All participants at Rockefeller University provided written informed consent before participation.
in the study and the study was conducted in accordance with Good Clinical Practice. For detailed participant characteristics see Supplementary Table 2.

398 **SARS-CoV-2 molecular tests**

Saliva was collected into guanidinium thiocyanate buffer as described. RNA was extracted using either a column-based (Qiagen QIAmp DSP Viral RNA Mini Kit, Cat#61904) or a magnetic bead-based method as described. Reverse transcribed cDNA was amplified using primers and probes validated by the CDC or by Columbia University Personalized Medicine Genomics Laboratory respectively and approved by the FDA under the Emergency Use Authorization. Viral RNA was considered detected if Ct for two viral primers/probes were <40.

**Blood samples processing and storage.**

Peripheral Blood Mononuclear Cells (PBMCs) obtained from samples collected at Rockefeller University were purified as previously reported by gradient centrifugation and stored in liquid nitrogen in the presence of FCS and DMSO. Heparinized plasma and serum samples were aliquoted and stored at -20 °C or less. Prior to experiments, aliquots of plasma samples were heat-inactivated (56 °C for 1 hour) and then stored at 4 °C.

**ELISAs**

ELISAs to evaluate antibodies binding to SARS-CoV-2 RBD and N were performed by coating of high-binding 96-half-well plates (Corning 3690) with 50 μl per well of a 1μg/ml protein solution in PBS overnight at 4 °C. Plates were washed 6 times with washing buffer (1× PBS with 0.05% Tween-20 (Sigma-Aldrich)) and incubated with 170 μl per well blocking buffer
PBS with 2% BSA and 0.05% Tween-20 (Sigma)) for 1 h at room temperature. Immediately after blocking, monoclonal antibodies or plasma samples were added in PBS and incubated for 1 h at room temperature. Plasma samples were assayed at a 1:66 starting dilution and 7 additional threefold serial dilutions. Monoclonal antibodies were tested at 10 μg/ml starting concentration and 10 additional fourfold serial dilutions. Plates were washed 6 times with washing buffer and then incubated with anti-human IgG, IgM or IgA secondary antibody conjugated to horseradish peroxidase (HRP) (Jackson Immuno Research 109-036-088 109-035-129 and Sigma A0295) in blocking buffer at a 1:5,000 dilution (IgM and IgG) or 1:3,000 dilution (IgA). Plates were developed by addition of the HRP substrate, TMB (ThermoFisher) for 10 min (plasma samples) or 4 minutes (monoclonal antibodies). The developing reaction was stopped by adding 50 μl 1 M H₂SO₄ and absorbance was measured at 450 nm with an ELISA microplate reader (FluoStar Omega, BMG Labtech) with Omega and Omega MARS software for analysis. For plasma samples, a positive control (plasma from participant COV72, diluted 66.6-fold and seven additional threefold serial dilutions in PBS) was added to every assay plate for validation. The average of its signal was used for normalization of all of the other values on the same plate with Excel software before calculating the area under the curve using Prism V9.1(GraphPad). For monoclonal antibodies, the EC50 was determined using four-parameter nonlinear regression (GraphPad Prism V9.1).

Proteins

Mammalian expression vectors encoding the RBDs of SARS-CoV-2 (GenBank MN985325.1; S protein residues 319-539) or K417N, E484K, N501Y RBD mutants with an N-terminal human
IL-2 or Mu phosphatase signal peptide were previously described. SARS-CoV-2 Nucleocapsid protein (N) was purchased from Sino Biological (40588-V08B).

SARS-CoV-2 pseudotyped reporter virus

A panel of plasmids expressing RBD-mutant SARS-CoV-2 spike proteins in the context of pSARS-CoV-2-SΔ19 has been described previously. Variant pseudoviruses resembling variants of concern B.1.1.7 (first isolated in the UK), B.1.351 (first isolated in South-Africa) and B.1.526 (first isolated in New York City) were generated by introduction of substitutions using synthetic gene fragments (IDT) or overlap extension PCR mediated mutagenesis and Gibson assembly. Specifically, the variant-specific deletions and substitutions introduced were:

- B.1.1.7: ΔH69/V70, ΔY144, N501Y, A470D, D614G, P681H, T761I, S982A, D118H
- B.1.351: D80A, D215G, L242H, R246I, K417N, E484K, N501Y, D614G, A701V
- B.1.526: L5F, T95I, D253G, E484K, D614G, A701V.

The E484K and K417N/E484K/N501Y (KEN) substitution, as well as the deletions/substitutions corresponding to variants of concern were incorporated into a spike protein that also includes the R683G substitution, which disrupts the furin cleavage site and increases particle infectivity.

Neutralizing activity against mutant pseudoviruses were compared to a wildtype SARS-CoV-2 spike sequence (NC_045512), carrying R683G where appropriate.

SARS-CoV-2 pseudotyped particles were generated as previously described. Briefly, 293T cells were transfected with pNL4-3ΔEnv-nanoluc and pSARS-CoV-2-SΔ19, particles were harvested 48 hpt, filtered and stored at -80°C.

Pseudotyped virus neutralization assay
Fourfold serially diluted plasma from COVID-19-convalescent individuals or monoclonal antibodies were incubated with SARS-CoV-2 pseudotyped virus for 1 h at 37 °C. The mixture was subsequently incubated with 293T_Ace2 cells (for comparisons of plasma or monoclonal antibodies from convalescent individuals) or HT1080Ace2 cl14 cells (for analyses involving mutant/variant pseudovirus panels), as indicated, for 48h after which cells were washed with PBS and lysed with Luciferase Cell Culture Lysis 5× reagent (Promega). Nanoluc Luciferase activity in lysates was measured using the Nano-Glo Luciferase Assay System (Promega) with the Glomax Navigator (Promega). The obtained relative luminescence units were normalized to those derived from cells infected with SARS-CoV-2 pseudotyped virus in the absence of plasma or monoclonal antibodies. The half-maximal neutralization titers for plasma (NT_{50}) or half-maximal and 90% inhibitory concentrations for monoclonal antibodies (IC_{50} and IC_{90}) were determined using four-parameter nonlinear regression (least squares regression method without weighting; constraints: top=1, bottom=0) (GraphPad Prism).

**Biotinylation of viral protein for use in flow cytometry**

Purified and Avi-tagged SARS-CoV-2 RBD or SARS-CoV-2 RBD KEN mutant (K417N, E484K, N501Y) was biotinylated using the Biotin-Protein Ligase-BIRA kit according to manufacturer’s instructions (Avidity) as described before. Ovalbumin (Sigma, A5503-1G) was biotinylated using the EZ-Link Sulfo-NHS-LC-Biotinylation kit according to the manufacturer’s instructions (Thermo Scientific). Biotinylated ovalbumin was conjugated to streptavidin-BV711 (BD biosciences, 563262) and RBD to streptavidin-PE (BD Biosciences, 554061) and streptavidin-AF647 (Biolegend, 405237).
Flow cytometry and single cell sorting

Single-cell sorting by flow cytometry was described previously. Briefly, peripheral blood mononuclear cells were enriched for B cells by negative selection using a pan-B-cell isolation kit according to the manufacturer’s instructions (Miltenyi Biotec, 130-101-638). The enriched B cells were incubated in FACS buffer (1× PBS, 2% FCS, 1 mM EDTA) with the following anti-human antibodies (all at 1:200 dilution): anti-CD20-PECy7 (BD Biosciences, 335793), anti-CD3-APC-eFluor 780 (Invitrogen, 47-0037-41), anti-CD8-APC-eFluor 780 (Invitrogen, 47-0086-42), anti-CD16-APC-eFluor 780 (Invitrogen, 47-0168-41), anti-CD14-APC-eFluor 780 (Invitrogen, 47-0149-42), as well as Zombie NIR (BioLegend, 423105) and fluorophore-labelled RBD and ovalbumin (Ova) for 30 min on ice. Single CD3-CD8-CD14-CD16-CD20+Ova-RBD-PE+RBD-AF647+ B cells were sorted into individual wells of 96-well plates containing 4 μl of lysis buffer (0.5× PBS, 10 mM DTT, 3,000 units/ml RNasin Ribonuclease Inhibitors (Promega, N2615) per well using a FACS Aria III and FACSDiva software (Becton Dickinson) for acquisition and FlowJo for analysis. The sorted cells were frozen on dry ice, and then stored at −80 °C or immediately used for subsequent RNA reverse transcription. For B cell phenotype analysis, in addition to above antibodies, B cells were also stained with following anti-human antibodies: anti-IgD-BV421 (Biolegend, 348226), anti-CD27-FITC (BD biosciences, 555440), anti-CD19-BV605 (Biolegend, 302244), anti-CD71- PerCP-Cy5.5 (Biolegend, 334114), anti-IgG-PECF594 (BD biosciences, 562538), anti-IgM-AF700 (Biolegend, 314538), anti-IgA-Viogreen (Miltenyi Biotec, 130-113-481).

Antibody sequencing, cloning and expression
Antibodies were identified and sequenced as described previously. In brief, RNA from single cells was reverse-transcribed (SuperScript III Reverse Transcriptase, Invitrogen, 18080-044) and the cDNA stored at −20 °C or used for subsequent amplification of the variable IGH, IGL and IGK genes by nested PCR and Sanger sequencing. Sequence analysis was performed using MacVector. Amplicons from the first PCR reaction were used as templates for sequence- and ligation-independent cloning into antibody expression vectors. Recombinant monoclonal antibodies were produced and purified as previously described.

**Biolayer interferometry**

Biolayer interferometry assays were performed as previously described. Briefly, we used the Octet Red instrument (ForteBio) at 30 °C with shaking at 1,000 r.p.m. Epitope-binding assays were performed with protein A biosensor (ForteBio 18-5010), following the manufacturer’s protocol ‘classical sandwich assay’. (1) Sensor check: sensors immersed 30 s in buffer alone (kinetics buffer 10x ForteBio 18-1105 diluted 1x in PBS1x). (2) Capture first antibody: sensors immersed 10 min with Ab1 at 30 μg/ml. (3) Baseline: sensors immersed 30 s in buffer alone. (4) Blocking: sensors immersed 5 min with IgG isotype control at 50 μg/ml. (6) Antigen association: sensors immersed 5 min with RBD at 100 μg/ml. (7) Baseline: sensors immersed 30 s in buffer alone. (8) Association Ab2: sensors immersed 5 min with Ab2 at 30 μg/ml. Curve fitting was performed using the Fortebio Octet Data analysis software (ForteBio). Affinity measurement of anti-SARS-CoV-2 IgGs binding were corrected by subtracting the signal obtained from traces performed with IgGs in the absence of WT RBD. The kinetic analysis using protein A biosensor (ForteBio 18-5010) was performed as follows: (1) baseline: 60sec immersion in buffer. (2) loading: 200sec immersion in a solution with IgGs 30 μg/ml. (3) baseline: 200sec immersion in
buffer. (4) Association: 300sec immersion in solution with WT RBD at 200, 100, 50 or 25 μg/ml
(5) dissociation: 600sec immersion in buffer. Curve fitting was performed using a fast 1:1
binding model and the Data analysis software (ForteBio). Mean $K_D$ values were determined by
averaging all binding curves that matched the theoretical fit with an $R^2$ value $\geq 0.8.$

**Computational analyses of antibody sequences**

Antibody sequences were trimmed based on quality and annotated using Igblastn v.1.14. with
IMGT domain delineation system. Annotation was performed systematically using Change-O
toolkit v.0.4.540. Heavy and light chains derived from the same cell were paired, and
clonotypes were assigned based on their V and J genes using in-house R and Perl scripts (Fig.
2d). All scripts and the data used to process antibody sequences are publicly available on GitHub
(https://github.com/stratust/igpipeline).

The frequency distributions of human V genes in anti-SARS-CoV-2 antibodies from this study
was compared to 131,284,220 IgH and IgL sequences generated by 45 and downloaded from
cAb-Rep46, a database of human shared BCR clonotypes available at https://cabc
rep.c2b2.columbia.edu/. Based on the 91 distinct V genes that make up the 6902 analyzed
sequences from Ig repertoire of the 10 participants present in this study, we selected the IgH and
IgL sequences from the database that are partially coded by the same V genes and counted them
according to the constant region. The frequencies shown in (Extended data Fig. 4) are relative to
the source and isotype analyzed. We used the two-sided binomial test to check whether the
number of sequences belonging to a specific IgHV or IgLV gene in the repertoire is different
according to the frequency of the same IgV gene in the database. Adjusted p-values were
calculated using the false discovery rate (FDR) correction. Significant differences are denoted with stars.

Nucleotide somatic hypermutation and CDR3 length were determined using in-house R and Perl scripts. For somatic hypermutations, IGHV and IGLV nucleotide sequences were aligned against their closest germlines using Igblastn and the number of differences were considered nucleotide mutations. The average mutations for V genes were calculated by dividing the sum of all nucleotide mutations across all participants by the number of sequences used for the analysis. To calculate the GRAVY scores of hydrophobicity we used Guy H.R. Hydrophobicity scale based on free energy of transfer (kcal/mole) implemented by the R package Peptides (the Comprehensive R Archive Network repository; https://journal.r-project.org/archive/2015/RJ-2015-001/RJ-2015-001.pdf). We used 2680 heavy chain CDR3 amino acid sequences from this study and 22,654,256 IGH CDR3 sequences from the public database of memory B cell receptor sequences. The two-tailed Wilcoxon matched-pairs signed rank test was used to test whether there is a difference in hydrophobicity distribution.

Immunoglobulins grouped into the same clonal lineage had their respective IgH and IgL sequences merged and subsequently aligned, using TranslatorX, with the unmutated ancestral sequence obtained from IMGT/V-QUEST reference directory. GCTree was further used to perform the phylogenetic trees construction. Each node represents a unique IgH and IgL combination and the size of each node is proportional to the number of identical sequences. The numbered nodes represent the unobserved ancestral genotypes between the germline sequence and the sequences on the downstream branch.
Competing interests: The Rockefeller University has filed a provisional patent application in connection with this work on which M.C.N. is an inventor (US patent 63/021,387). The patent has been licensed by Rockefeller University to Bristol Meyers Squib.

Data availability statement: Data are provided in SI Tables 1-8. The raw sequencing data and computer scripts associated with Figure 2 have been deposited at Github (https://github.com/stratust/igpipeline). This study also uses data from “A Public Database of Memory and Naive B-Cell Receptor Sequences” (https://doi.org/10.5061/dryad.35ks2), PDB (6VYB and 6NB6) and from “High frequency of shared clonotypes in human B cell receptor repertoires” (https://doi.org/10.1038/s41586-019-0934-8).

Code availability statement: Computer code to process the antibody sequences is available at GitHub (https://github.com/stratust/igpipeline).

Data presentation

Figures arranged in Adobe Illustrator 2020.

Acknowledgements: We thank all study participants who devoted time to our research; The Rockefeller University Hospital nursing staff and Clinical Research Support Office and nursing staff. Mayu Okawa Frank, Marissa Bergh, and Robert B. Darnell for SARS-CoV-2 saliva PCR testing. Charles M. Rice, Pamela J. Bjorkman and all members of the M.C.N. laboratory for helpful discussions and Maša Jankovic for laboratory support. This work was supported by NIH grant P01-AI138398-S1 (M.C.N.) and 2U19AI111825 (M.C.N.). R37-AI64003 to P.D.B.; R01AI78788.
to T.H.; We thank Dr. Jost Vielmetter and the Protein Expression Center in the Beckman Institute at Caltech for expression assistance. C.O.B. is supported by the HHMI Hanna Gray and Burroughs Wellcome PDEP fellowships. C.G. was supported by the Robert S. Wennett Post-Doctoral Fellowship, in part by the National Center for Advancing Translational Sciences (National Institutes of Health Clinical and Translational Science Award program, grant UL1 TR001866), and by the Shapiro-Silverberg Fund for the Advancement of Translational Research. P.D.B. and M.C.N. are Howard Hughes Medical Institute Investigators.

Author Contributions: P.D.B., T.H., and M.C.N. conceived, designed and analyzed the experiments. M. Caskey and C.G. designed clinical protocols. Z.W., F.M., D.S.B., S.F., C.V., J.D.S., E.B., C.O.B., F.S., A.C., and M.J. carried out experiments. A.G. and M. Cipolla produced antibodies. D.S.B., M.D., M.T., K.G.M., C.G. and M. Caskey recruited participants, executed clinical protocols and processed samples. T.Y.O. and V.R. performed bioinformatic analysis. Z.W., F.M, D.S.B., C.G. and M.C.N. wrote the manuscript with input from all co-authors.

Extended Data Figures
**Extended Data Fig. 1 Clinical correlations.** a-d, Association of persistence of symptoms (Sx) 12 months after infection with various clinical and serological parameters. 

a-b, Acute disease severity as assessed with the WHO Ordinal Scale of Clinical Improvement (a) and duration of acute phase symptoms (b) in individuals reporting persistent symptoms (+) compared to individuals who are symptom-free (-) 12 months post-infection. 

c, Proportion of individuals reporting persistent symptoms (black area) compared to individuals who are symptom-free (grey area) 12 months after infection grouped by vaccination status. 

d, Anti-RBD IgG, anti-N IgG, NT50 titers as well as the RBD/N IgG ratio at 12 months after infection in individuals reporting persistent symptoms (+) compared to individuals who are symptom-free (-) 12 months post-infection. 

Statistical significance was determined using the Mann-Whitney test in a, b and d, and using the Fisher’s exact test in c.
Extended Data Fig. 2: Plasma activity. a-h, ELISA results for plasma against SARS-CoV-2 RBD 12 months after infection (N=63). Non-vaccinated individuals are depicted with black circles.
and lines, and vaccinated individuals are depicted in blue throughout. Two outlier individuals who received their first dose of vaccine 24–48 hours before sample collection are depicted as purple circles. **a-h**, IgM (**a-d**) and IgA (**e-h**) antibody binding to SARS-CoV-2 RBD 12 months after infection. **a, e**, ELISA curves from non-vaccinated (black lines) individuals, as well as individuals who received one or two doses (blue lines) of a COVID-19 mRNA vaccine (left panels). Area under the curve (AUC) over time in non-vaccinated (**b and f**) and vaccinated individuals (**c and g**). Lines in **b, c, f, g** connect longitudinal samples. **d, h**, Boxplots showing AUC values of all 63 individuals, as indicated. **i-r**, Correlation of serological parameters in non-vaccinated (black circles and black statistics) and vaccinated (blue circles and blue statistics) individuals. Two individuals who received their first dose of vaccine 24–48 hours before sample collection are depicted as purple circles. **i-k**, Correlation of 12-month titers of anti-RBD IgG and NT50 (**i**), anti-RBD IgG and N IgG (**j**), and anti-N IgG and NT50 (**k**). **l-n**, Correlation of remaining plasma titers at 12 months (expressed as the fraction of 1.3-month titers on the Y axis) and participant age for anti-RBD IgG (**l**), anti-N IgG (**m**), and NT50 (**n**). **o-s**, Correlation of remaining plasma titers at 12 months (expressed as the relative change from 1.3-month titers on the Y axis) and initial plasma titers at 1.3 months for anti-RBD IgG (**o**), anti-RBD IgM (**p**), anti-RBD IgA (**q**), anti-N IgG (**m**), and NT50 (**s**). Statistical significance was determined using the Spearman correlation test for the non-vaccinated and vaccinated subgroups independently. For **a-s** all experiments were performed at least in duplicate.
Extended Data Fig. 3: Flow cytometry. a, Gating strategy. Gating was on singlets that were CD20⁺ or CD19⁺ and CD3-CD8-CD16-Ova⁻. Anti-IgG, IgM, IgA, IgD, CD71 and CD27 antibodies were used for B cell phenotype analysis. Sorted cells were RBD-PE⁺ and RBD/KEN-AF647⁺. b and c, Flow cytometry showing the percentage of RBD-double positive (b) and 647-K417N/E484K/N501Y mutant RBD cross-reactive (c) memory B cells from 1.3 or 6- and 12-months post-infection in 10 selected participants. d, as in Fig. 2c, Pie charts show the distribution of antibody sequences from 4 individuals after 1.3³ (upper panel) or 6.2⁴ months (middle panel) or 12 months (lower panel). e, As in b and c, graph summarizes cell number (per 2 million B cells) of immunoglobulin class of antigens binding memory B cells in samples obtained at 1.3, 6.2 and 12 months. f, same as in d, but summarizes percentage of CD71 positive activated antigen specific B cells. Each dot is one individual. Red horizontal bars indicate mean values. Statistical significance was determined using two-tailed Mann–Whitney U-tests.
Extended Data Fig. 4: Frequency distribution of human V genes. Graph shows comparison of the frequency distributions of human V genes of anti-SARS-CoV-2 antibodies from donors at 1.3, 6.2, 12 months after infection. a, Graph shows relative abundance of human IGVH genes Sequence Read Archive accession SRP010970 (green), convalescent vaccinees (blue), and convalescent non-vaccinees (orange). Statistical significance was determined by two-sided binomial test. b and c, same as in a, but showing comparison between antibodies from donors at 1.3 months (b), 6.2 months (c), and 12 months after infection.
**Extended Data Fig. 5: Analysis of anti-RBD antibodies.**

**a,** as in Fig. 2e, graph shows number of clonally expanded B cells (per 10 million B cells) at both time points from four individuals.
Cells belonging the same clone are marked in the same color. Statistical significance was determined using Wilcoxon matched-pairs signed rank tests. Vaccinees are marked in red.  

Number of somatic nucleotide mutations in the IGVH (top) and IGVL (bottom) in antibodies obtained after 1.3 or 6.2 or 12 months from the indicated individual.  

c. same as b, but graphs show comparison between new clones and conserved clones in 6 vaccinated convalescent individuals at 12 months after infection.  

d. The amino acid length of the CDR3s at the IGVH and IGVL for each individual. Right panel shows all antibodies combined. The horizontal bars indicate the mean.  

Statistical significance was determined using two-tailed Mann–Whitney U-tests.
Extended Data Fig. 6: Evolution of anti-SARS-CoV-2 RBD antibody clone. Clonal evolution of RBD-binding memory B cells from ten convalescent individuals, a, phylogenetic tree graph shows clones from convalescent non-vaccinees, b, same as a, but from convalescent vaccinees. Numbers refer to mutations compared to the preceding vertical node. Colors indicate timepoint;
grey, orange and red represent 1.3, 6 and 12 months respectively, black dots indicate inferred nodes, and size is proportional to sequence copy number; GL = germline sequence.
Extended Data Fig. 7: Neutralization of WT RBD pseudovirus by mAbs. **A,b,** Binding curves (**a**) and EC50 dot plot (**b**) of mAbs isolated from non-vaccinated (black curves and dots) and from vaccinated (blue curves and dots) convalescents individuals 12 months after infection. **c-e,** IC50 values of mAbs isolated 12 months after infection from non-vaccinated and vaccinated individuals. **c** shows all 12-month antibodies irrespective of clonality, **d** shows singlets only, and **e** shows only antibodies belonging to a clone or shared over time. Statistical significance was determined using Mann-Whitney test. Geometric mean IC50 is indicated in red. **f,** IC50 values of shared clones of mAbs cloned from B-cells from the initial 1.3- and 6.2, as well as 12-month follow-up visit, divided by participant, as indicated. Lines connect clonal antibodies shared between time points. Antibodies with IC50>1000ng/ml are plotted at 1000 ng/ml. Average IC50 values of two independent experiments are shown.
Extended Data Fig. 8: Biolayer interferometry affinity measurements. a-b, Graphs depict affinity measurements of neutralizing (green) and non-neutralizing (red) antibodies isolated 1.3 months (a) or 12 months (b) after infection.
Extended Data Fig. 9: Biolayer interferometry antibody competition experiment. a-b, Anti-SARS-CoV-2 RBD antibodies isolated 1.3 (a) or 12 months (b) after infection were assayed for competition with structurally characterized anti-RBD antibodies by biolayer interferometry experiments as in Fig 4a. Graphs represent the binding of the second antibody (2nd Ab) to preformed first antibody (1st Ab)–RBD complexes. Dotted line denotes when 1st Ab and 2nd Ab are the same. For each antibody group identified in Fig 4c the left graphs represent the binding of the class-representative C144, C121, C135 or C105 3,20 (2nd Ab) to the candidate antibody (1st Ab)-RBD complex. The right graphs represent the binding of the candidate antibody (2nd Ab) to the complex of C144-RBD, C121-RBD, C135-RBD or C105-RBD (1st Ab). Antibodies belonging to the same groups are indicated to the left of the respective curves.
Supplementary Tables

Supplementary Table 1: Cohort summary

Supplementary Table 2: Individual participant characteristics

Supplementary Table 3: Antibody sequences from patients is provided as a separate Excel file.

Supplementary Table 4: Sequences, half maximal effective concentrations (EC50s) and inhibitory concentrations (IC50s) of the cloned monoclonal antibodies is provided as a separate Excel file.

Supplementary Table 5: Binding and Neutralization activity of mAbs against mutant SARS-CoV-2 pseudoviruses.

Supplementary Table 6: Neutralization activity of mAbs against mutant SARS-CoV-2 pseudoviruses - Random potently neutralizing antibodies isolated at 1.3 and 12 months

Supplementary Table 7: Antibody affinities and neutralization - Clonal pairs isolated at 1.3 and 12 months

Supplementary Table 8: Neutralization activity of mAbs against mutant SARS-CoV-2 pseudoviruses - Clonal pairs isolated at 1.3 and 12 months.
Reference:

1. Davies, N. G. et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science* **372**, doi:10.1126/science.abg3055 (2021).

2. Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *Nature* **592**, 616-622, doi:10.1038/s41586-021-03324-w (2021).

3. Robbiani, D. F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature* **584**, 437-442, doi:10.1038/s41586-020-2456-9 (2020).

4. Gaebler, C. et al. Evolution of antibody immunity to SARS-CoV-2. *Nature* **591**, 639-644, doi:10.1038/s41586-021-03207-w (2021).

5. Goel, R. R. et al. Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination. *Sci Immunol* **6**, doi:10.1126/sciimmunol.abi6950 (2021).

6. Saadat, S. et al. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. *JAMA* **325**, 1467-1469, doi:10.1001/jama.2021.3341 (2021).

7. Krammer, F. et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *N Engl J Med* **384**, 1372-1374, doi:10.1056/NEJMct2101667 (2021).

8. Reynolds, C. J. et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. *Science*, doi:10.1126/science.abh1282 (2021).

9. Muecksch, F. et al. Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies. *bioRxiv*, doi:10.1101/2021.03.07.434175 (2021).

10. Schmidt, F. et al. Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. *J Exp Med* **217**, doi:10.1084/jem.20201181 (2020).

11. Tegally, H. et al. Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature* **592**, 438-443, doi:10.1038/s41586-021-03402-9 (2021).

12. West, A. P. et al. Detection and characterization of the SARS-CoV-2 lineage B.1.526 in New York. *bioRxiv*, 2021.2021.02.14.431043, doi:10.1101/2021.02.14.431043 (2021).

13. Inoue, T. et al. Exit from germinal center to become quiescent memory B cells depends on metabolic reprogramming and provision of a survival signal. *J Exp Med* **218**, doi:10.1084/jem.20200866 (2021).

14. Viant, C. et al. Antibody Affinity Shapes the Choice between Memory and Germinal Center B Cell Fates. *Cell* **183**, 1298-1311 e1211, doi:10.1016/j.cell.2020.09.063 (2020).

15. Stamatatos, L. et al. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. *Science*, doi:10.1126/science.abg9175 (2021).

16. Sokal, A. et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. *Cell* **184**, 1201-1213 e1214, doi:10.1016/j.cell.2021.01.050 (2021).

17. Sakharkar, M. et al. Prolonged evolution of the human B cell response to SARS-CoV-2 infection. *Sci Immunol* **6**, doi:10.1126/sciimmunol.abg6916 (2021).

18. Brouwer, P. J. M. et al. Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. *Science* **369**, 643-650, doi:10.1126/science.abc5902 (2020).
Rogers, T. F. et al. Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. *Science* **369**, 956-963, doi:10.1126/science.abc7520 (2020).

Barnes, C. O. *et al.* SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. *Nature* **588**, 682-687, doi:10.1038/s41586-020-2852-1 (2020).

Hoffmann, M. *et al.* SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280 e278, doi:10.1016/j.cell.2020.02.052 (2020).

Greaney, A. J. *et al.* Mutational escape from the polyclonal antibody response to SARS-CoV-2 infection is largely shaped by a single class of antibodies. *bioRxiv*, doi:10.1101/2021.03.17.435863 (2021).

Weisblum, Y. *et al.* Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. *Elife* **9**, doi:10.7554/eLife.61312 (2020).

Elsner, R. A. & Shlomchik, M. J. Germinal Center and Extrafollicular B Cell Responses in Vaccination, Immunity, and Autoimmunity. *Immunity* **53**, 1136-1150, doi:10.1016/j.immuni.2020.11.006 (2020).

Lau, A. W. & Brink, R. Selection in the germinal center. *Curr Opin Immunol* **63**, 29-34, doi:10.1016/j.coi.2019.11.001 (2020).

Victora, G. D. & Nussenzweig, M. C. Germinal centers. *Annu Rev Immunol* **30**, 429-457, doi:10.1146/annurev-immunol-020711-075032 (2012).

Inoue, T., Moran, I., Shinnakasu, R., Phan, T. G. & Kurosaki, T. Generation of memory B cells and their reactivation. *Immunol Rev* **283**, 138-149, doi:10.1111/imr.12640 (2018).

Taylor, J. J., Pape, K. A., Steach, H. R. & Jenkins, M. K. Humoral immunity. Apoptosis and antigen affinity limit effector cell differentiation of a single naive B cell. *Science* **347**, 784-787, doi:10.1126/science.aaa1342 (2015).

McKean, D. *et al.* Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. *Proc Natl Acad Sci U S A* **81**, 3180-3184, doi:10.1073/pnas.81.10.3180 (1984).

Petersen, M. S. *et al.* SARS-CoV-2 natural antibody response persists up to 12 months in a nationwide study from the Faroe Islands. *medRxiv*, 2021.2004.2019.21255720, doi:10.1101/2021.04.19.21255720 (2021).

Li, C. *et al.* Twelve-month specific IgG response to SARS-CoV-2 receptor-binding domain among COVID-19 convalescent plasma donors in Wuhan. *bioRxiv*, 2021.2004.2005.437224, doi:10.1101/2021.04.05.437224 (2021).

Turner, J. *et al.* SARS-CoV-2 mRNA vaccines induce a robust germinal centre reaction in humans. *Research Square*, doi:https://www.researchsquare.com/article/rs-310773/v1 (2021).

Greaney, A. J. *et al.* The SARS-CoV-2 mRNA-1273 vaccine elicits more RBD-focused neutralization, but with broader antibody binding within the RBD. *bioRxiv*, doi:10.1101/2021.04.14.439844 (2021).

Wang, Z. *et al.* Enhanced SARS-CoV-2 neutralization by dimeric IgA. *Sci Transl Med* **13**, doi:10.1126/scitransmed.abf1555 (2021).

Schoof, M. *et al.* An ultrapotent synthetic nanobody neutralizes SARS-CoV-2 by stabilizing inactive Spike. *Science* **370**, 1473-1479, doi:10.1126/science.abe3255 (2020).
De Gasparo, R. et al. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. *Nature*, doi:10.1038/s41586-021-03461-y (2021).

Xu, J. et al. Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants. *bioRxiv*, doi:10.1101/2021.03.04.433768 (2021).

Wu, F. et al. A new coronavirus associated with human respiratory disease in China. *Nature* **579**, 265-269, doi:10.1038/s41586-020-2008-3 (2020).

Chomczynski, P. & Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. *Analytical biochemistry* **162**, 156-159, doi:10.1006/abio.1987.9999 (1987).

DeAngelis, M. M., Wang, D. G. & Hawkins, T. L. Solid-phase reversible immobilization for the isolation of PCR products. *Nucleic Acids Res* **23**, 4742-4743, doi:10.1093/nar/23.22.4742 (1995).

Grifoni, A. et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. *Cell* **181**, 1489-1501 e1415, doi:10.1016/j.cell.2020.05.015 (2020).

Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med* **26**, 1033-1036, doi:10.1038/s41591-020-0913-5 (2020).

Barnes, C. O. et al. Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. *Cell* **182**, 828-842 e816, doi:10.1016/j.cell.2020.06.025 (2020).

Gupta, N. T. et al. Change-O: a toolkit for analyzing large-scale B cell immunoglobulin repertoire sequencing data. *Bioinformatics (Oxford, England)* **31**, 3356-3358, doi:10.1093/bioinformatics/btv359 (2015).

Soto, C. et al. High frequency of shared clonotypes in human B cell receptor repertoires. *Nature* **566**, 398-402, doi:10.1038/s41586-019-0934-8 (2019).

Guo, Y., Chen, K., Kwong, P. D., Shapiro, L. & Sheng, Z. cAb-Rep: A Database of Curated Antibody Repertoires for Exploring Antibody Diversity and Predicting Antibody Prevalence. *Front Immunol* **10**, 2365, doi:10.3389/fimmu.2019.02365 (2019).

Kyte, J. & Doolittle, R. F. A simple method for displaying the hydropathic character of a protein. *J Mol Biol* **157**, 105-132, doi:10.1016/0022-2836(82)90515-0 (1982).

Guy, H. R. Amino acid side-chain partition energies and distribution of residues in soluble proteins. *Biophysical journal* **47**, 61-70, doi:10.1016/S0006-3495(85)83877-7 (1985).

DeWitt, W. S. et al. A Public Database of Memory and Naive B-Cell Receptor Sequences. *PLoS One* **11**, e0160853, doi:10.1371/journal.pone.0160853 (2016).

Abascal, F., Zardoya, R. & Telford, M. J. TranslatorX: multiple alignment of nucleotide sequences guided by amino acid translations. *Nucleic Acids Res* **38**, W7-13, doi:10.1093/nar/gkq291 (2010).

Lefranc, M. P. IMGT, the International ImMunoGeneTics Information System. *Cold Spring Harb Protoc* **2011**, 595-603, doi:10.1101/pdb.top115 (2011).

DeWitt, W. S., 3rd, Mesin, L., Victoria, G. D., Minin, V. N. & Matsen, F. A. t. Using Genotype Abundance to Improve Phylogenetic Inference. *Mol Biol Evol* **35**, 1253-1265, doi:10.1093/molbev/msy020 (2018).